Skip to main content

Balance and effectiveness of research and innovation spending inquiry

Inquiry

In May 2018, UK Research & Innovation (UKRI) published its Strategic Prospectus, which represents “the beginning of the process to develop a detailed Research and Innovation Strategy”. It states that “We will work with Government to develop a plan for meeting this target [to increase the UK’s investment in research and development to 2.4% of GDP by 2027, and in the future to 3%], maximising the impact of public investment in research and innovation, and supporting business and other partners to invest more.” It envisages ongoing work on “what constitutes reasonable balance” of its funding.

Reports, special reports and government responses

View all reports and responses
21st Report - Balance and effectiveness of research and innovation spending
Inquiry Balance and effectiveness of research and innovation spending inquiry
HC 1453
Report

Oral evidence transcripts

View all oral evidence transcripts
26 March 2019
Inquiry Balance and effectiveness of research and innovation spending inquiry
Witnesses Sir Mark Walport, Chief Executive, and Rebecca Endean, Director of Strategy, UK Research and Innovation; Chris Skidmore MP, Minister of State for Universities, Science, Research and Innovation, Jenny Dibden, Director, Science Research and Innovation, and Harriet Wallace, Director, International Science and Innovation Directorate, Department for Business, Energy and Industrial Strategy
Oral Evidence
28 February 2019
Inquiry Balance and effectiveness of research and innovation spending inquiry
Witnesses Professor Graeme Reid, Professor of Science and Research Policy, UCL, Professor Colette Fagan, Russell Group, and Gordon McKenzie, Chief Executive, GuildHE; Dr Peter O’Brien, Executive Director, Yorkshire Universities, Professor Jonathan Seckl, Vice-Principal, Planning, Resources and Research Policy, University of Edinburgh, Professor Anthony Hollander, Pro-Vice Chancellor for Research and Impact, University of Liverpool, and Sarah Haywood, Chief Executive, MedCity
Oral Evidence
18 December 2018
Inquiry Balance and effectiveness of research and innovation spending inquiry
Witnesses Keith Thompson, Chair, Catapult CEO network, and CEO, Cell and Gene Therapy Catapult, Professor Richard Brook, President, Association of Innovation, Research & Technology Organisations, David Connell, Senior Research Fellow, Centre for Business Research, Cambridge Judge Business School, and Felicity Burch, Director of Innovation and Digital, Confederation of British Industry; Dr Robert Massey, Deputy Executive Director, Royal Astronomical Society, Professor Dame Ann Dowling, President, Royal Academy of Engineering, Professor Neil Hall, Director, Earlham Institute, and Dr Charmaine Griffiths, Chief Operating Officer, The Institute of Cancer Research
Oral Evidence
Intergenerational Foundation (BER0103)
Miricyl (BER0106)
Denise Yates (BER0105)

Other publications

No other publications published.

Contact us

We can’t usually help you with an individual problem or a specific complaint.

  • Email: commonssitc@parliament.uk
  • Phone: 020 7219 5023 (general enquiries) | 020 7219 4984 (media enquiries)
  • Address: Science, Innovation and Technology Committee, House of Commons, London, SW1A 0AA